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Like a pendulum, the therapeutic recommendations to
initiate antiretroviral therapy (ART) have changed over
the last two decades. Indeed, initiation of ART has swung
from an initial “treat hard and early”, to a CD4 T cell
count spanning from 200 to 500 and recently to a “as soon
as the patient is ready”. Changes on the optimal timing to
initiate ART were based on the following 1) Availability of
new ART with increased potency, improved tolerance and
reduced pill burden; 2) Evidence that controlled viral repli-
cation on ART is associated with a dramatic decrease in
HIV transmission; 3) New insights on HIV pathogenesis
and on the establishment and maintenance of HIV
reservoirs.
Recent findings on HIV pathogenesis concerning the
relationships between CD4 T cell counts, immune activa-
tion, non-infectious clinical events and cancers will be pre-
sented. Specifically, the influence of CD4 nadir on the
quality of long-term immune reconstitution and viral
reservoir persistence following ART initiation will be high-
lighted. We will also focus on the clinical relevance of
maintaining certain CD4 T cell subsets like central mem-
ory pool for an optimal cytotoxic HIV-specific and vacci-
nation responses. We will also revisit the tissue and
cellular localizations of HIV reservoirs according to the
time of treatment initiation. Furthermore, ethical consid-
erations on a “patient-centered medicine” for early ART
initiation will be discussed. Particularly, the advantages
and inconveniences of a life-long treatment on a patient’s
quality of life, drug-resistance development, long-term
drug toxicity, cost and observance issues will be presented.
The very early ART initiation reveals a new frontier 1)
Allowing for some patients an ART-free viral control
post-drug discontinuation era 2) Selecting optimal patients
harboring a reduced HIV reservoir to be invited to partici-
pate in clinical trials aiming to HIV eradication. We are
entering in a new era where “Treating early to be able to
stop early” will be the focus of our future collaborating
research efforts to vividly improve the life of HIV-infected
people.
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